Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-05-16 Purchase |
2024-05-20 9:33 pm |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
1,724,137 | $2.9 | $4,999,997 | 10,099,279 (Indirect Direct) |
View |
| 2024-01-30 Purchase |
2024-03-06 9:52 pm |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
190 | $3.595 | $683 | 819,590 (Direct) |
View |
| 2023-12-18 Sale |
2023-12-20 4:26 pm |
Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director |
18,640 | $2.6994 | $50,317 | 62,456 (Direct) |
View |
| 2023-08-07 Sale |
2023-08-09 4:07 pm |
Allogene Therapeutics Inc. | ALLO | Mayo Stephen Director |
10,000 | $4.2855 | $42,855 | 25,328 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-05-16 Option Award |
2024-05-20 9:33 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
344,828 | $2.9 | 10,099,279 (Indirect) |
View |
| 2024-05-16 Option Award |
2024-05-20 6:02 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
344,828 | $2.9 | 1,164,418 (Direct) |
View |
| 2024-05-16 Option Award |
2024-05-20 6:01 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
344,828 | $2.9 | 7,723,302 (Direct) |
View |
| 2024-04-22 Tax Withholding |
2024-04-24 4:18 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer |
17,360 | $3.4671 | 265,459 (Direct) |
View |
| 2024-03-14 Tax Withholding |
2024-03-18 8:10 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
53,393 | $4.33 | 7,378,474 (Direct) |
View |
| 2024-01-25 Option Award |
2024-01-31 5:51 pm |
N/A 2034-01-25 |
Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer |
438,115 | $0 | 624,334 (Direct) |
View |
| 2024-01-25 Option Award |
2024-01-31 5:48 pm |
N/A 2034-01-25 |
Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel |
189,578 | $0 | 625,412 (Direct) |
View |
| 2024-01-25 Option Award |
2024-01-31 5:47 pm |
N/A 2034-01-25 |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
133,339 | $0 | 923,339 (Direct) |
View |
| 2024-01-25 Option Award |
2024-01-31 5:46 pm |
N/A 2034-01-25 |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
961,371 | $0 | 9,319,579 (Direct) |
View |
| 2024-01-25 Option Award |
2024-01-31 5:45 pm |
N/A 2034-01-25 |
Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D |
634,949 | $0 | 1,010,202 (Direct) |
View |
| 2024-01-25 Option Award |
2024-01-31 5:42 pm |
N/A 2034-01-25 |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
1,441,335 | $0 | 8,549,934 (Direct) |
View |
| 2024-01-22 Tax Withholding |
2024-01-24 5:25 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D |
24,690 | $3.1744 | 375,253 (Direct) |
View |
| 2023-10-16 Option Award |
2023-10-17 5:02 pm |
N/A 2033-10-16 |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
1,740,000 | $0 | 1,740,000 (Direct) |
View |
| 2023-08-14 Option Award |
2023-08-17 6:57 pm |
N/A 2033-08-14 |
Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin GENERAL COUNSEL |
1,396,688 | $0 | 1,396,688 (Direct) |
View |
| 2023-08-10 Option Award |
2023-08-14 7:59 pm |
N/A 2033-08-10 |
Allogene Therapeutics Inc. | ALLO | CHEN YINLIN JACK SVP, Finance |
50,561 | $0 | 128,041 (Direct) |
View |
Ownership |
2023-08-14 7:28 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | CHEN YINLIN JACK SVP, Finance |
0 | $0 | 272,725 (Direct) |
View |
| 2023-06-13 Option Award |
2023-06-15 5:06 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director |
74,561 | $0 | 81,096 (Direct) |
View |
| 2023-06-13 Option Award |
2023-06-15 5:03 pm |
N/A 2033-06-13 |
Allogene Therapeutics Inc. | ALLO | Barrett Elizabeth A. Director |
116,120 | $0 | 116,120 (Direct) |
View |
| 2023-06-13 Option Award |
2023-06-15 5:02 pm |
N/A 2033-06-13 |
Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director |
82,873 | $0 | 124,324 (Direct) |
View |
| 2023-06-13 Option Award |
2023-06-15 5:01 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Humer Franz B Director |
74,561 | $0 | 266,453 (Direct) |
View |
| 2023-06-13 Option Award |
2023-06-15 5:00 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
74,561 | $0 | 292,832 (Direct) |
View |
| 2023-06-13 Option Award |
2023-06-15 4:57 pm |
N/A 2033-06-13 |
Allogene Therapeutics Inc. | ALLO | Mayo Stephen Director |
116,120 | $0 | 116,120 (Direct) |
View |
| 2023-06-13 Option Award |
2023-06-15 4:56 pm |
N/A 2033-06-13 |
Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director |
116,120 | $0 | 116,120 (Direct) |
View |
| 2023-04-24 Option Award |
2023-04-26 5:20 pm |
N/A 2033-04-24 |
Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer |
1,017,243 | $0 | 1,017,243 (Direct) |
View |
| 2023-04-03 Option Award |
2023-04-05 6:43 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Smith Lillian VP, Corporate Counsel |
56,545 | $0 | 140,390 (Direct) |
View |
Ownership |
2023-04-05 6:38 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Smith Lillian VP, Corporate Counsel |
0 | $0 | 229,674 (Direct) |
View |
| 2023-03-22 Option Award |
2023-03-24 8:19 pm |
N/A 2033-03-22 |
Allogene Therapeutics Inc. | ALLO | MOORE ALISON Chief Technical Officer |
990,832 | $0 | 1,105,469 (Direct) |
View |
| 2023-03-22 Option Award |
2023-03-24 8:17 pm |
N/A 2033-03-22 |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
990,832 | $0 | 2,447,772 (Direct) |
View |
| 2023-03-22 Option Award |
2023-03-24 8:16 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D |
148,035 | $0 | 399,943 (Direct) |
View |
| 2023-03-22 Option Award |
2023-03-24 8:14 pm |
N/A 2033-03-22 |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
2,277,776 | $0 | 9,353,008 (Direct) |
View |
| 2023-03-22 Option Award |
2023-03-24 8:13 pm |
N/A 2033-03-22 |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
3,416,664 | $0 | 8,599,307 (Direct) |
View |
| 2023-03-14 Tax Withholding |
2023-03-16 5:32 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
22,340 | $5.56 | 5,182,643 (Direct) |
View |
| 2023-03-14 Tax Withholding |
2023-03-16 5:08 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
35,879 | $5.47 | 1,456,940 (Direct) |
View |
| 2023-03-14 Tax Withholding |
2023-03-16 4:49 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | MOORE ALISON Chief Technical Officer |
8,351 | $5.5071 | 114,637 (Direct) |
View |